The league table of top-selling drugs by global revenues saw a considerable shake-up in 2023, as COVID-19 vaccine and therapeutic sales plummeted, GLP-1 inhibitors took the market by storm, and one-time best-seller Humira lost US patent protection.
One of the most notable features of the top 20 list in 2023 was the huge fall in aggregate revenues....



![[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space](https://web.insights.norstella-labs.com/resizer/v2/G3M6E2FVDNOJPCEXELJNOIKH64.jpg?smart=true&auth=b5d5c6477bcbd6c122699f47191cbafe560695783f500a6e7b10c4d270965bdc&width=400&height=225)
